Who is sponsoring NCT02037672?

NCT02037672 is sponsored by University Medical Centre Ljubljana.

What condition does NCT02037672 study?

NCT02037672 studies PCOS, Obesity.

What drugs are being tested in NCT02037672?

Interventions: metformin, metformin and roflumilast.

What is the status of NCT02037672?

NCT02037672 is currently COMPLETED.

Last reviewed 2014-01-21 · How we verify

Combined Treatment With PDE-4 Inhibitor Roflumilast and Metformin Leads to Significant Weight Loss in Obese Women With Polycystic Ovary Syndrome

NCT02037672 Phase 4 COMPLETED

The purpose of this study was to determine whether combined treatment with phosphodiesterase-4 (PDE-4) inhibitor roflumilast and metformin is more effective than metformin as monotherapy in the treatment of obese women with polycystic ovary syndrome (PCOS) who had been previously poor responders regarding weight reduction on metformin monotherapy. The investigators anticipated greater changes in body weight in patients on combined treatment than in those on monotherapy with metformin.

Details

Lead sponsor	University Medical Centre Ljubljana
Phase	Phase 4
Status	COMPLETED
Enrolment	36
Start date	2013-09
Completion	2014-01

Conditions

PCOS
Obesity

Interventions

metformin
metformin and roflumilast

Primary outcomes

The main outcome was change in body weight. — Patient's body weight was mesured at the base point and every four weeks during 12 weeks of clinical trial.
The patient's body weight was measured in kilograms.

Countries

Slovenia